CARD Trial: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Video

Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.

Related Videos
Chad A. Hamilton, MD, an expert on ovarian cancer
Chad A. Hamilton, MD, an expert on ovarian cancer
Related Content